Major factors contributing to the growth of the global respiratory drug market include increasing prevalence of chronic respiratory diseases such as asthma and COPD. This is mainly owing to increasing smoking and pollution across the globe. Growing cases of respiratory diseases in new born and children and changing lifestyle and rise in obesity are fueling the market growth. Moreover, innovations and development of new drugs such as Dupilumab for severe asthma is significantly contributing in the market growth. However, reimbursements and strict government regulations and limited awareness and availability are some of the factors hindering the growth of the market. Lack of awareness among population of emerging countries is hampering the growth of the global respiratory drug market. However, robust pipeline products and emerging markets is expected to fuel the market growth in the near future.
The global respiratory drug market can be segmented on the basis of drug, drug class, route of administration, and end user. The market by drug class is segmented on the basis of currently available medication options for the treatment of symptoms of respiratory disorders reduce the symptoms for disease control. Generally, six classes of drug and nasal saline are used to treat asthma, oral and topical H1-antihistamines, mast cell stabilizers (i.e., cromones), decongestants, anticholinergic agents, and leukotriene inhibitors. Medications used for asthma are characteristically administered orally or intranasally. The intranasal route allows higher concentrations of the drug to be delivered, thus minimizing systemic side effects.
The global respiratory drug market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global respiratory drug market, followed by Europe. This is mainly owing to rising prevalence of chronic respiratory diseases in the region, especially in the US. The increasing research and development in respiratory drug development is expected to further drive the growth of the respiratory drug market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are increasing investment by pharmaceuticals companies. For instance, in India, India’s Cipla expects to double respiratory drug sales by 2020. Further, Indian companies such as Dr Reddy’s Laboratories, Lupin and Cipla are expected to build expertise in the respiratory drug market.
Some of the key players operating in the global respiratory drug market are GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, AstraZeneca PLC, Merck & Co., Inc., Novartis International AG, Omron Corporation, and Sunovion Pharmaceuticals Inc. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance,
The market study of respiratory drug market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic public databases such as American Academy of Family Physicians (aafp.org), org, and effectivenessevaluation.org.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for hospitals, private companies, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.
Global respiratory drug market is segmented on the basis of regional outlook and following segments:
Global Respiratory drug market Research and Analysis, By Drug
Global Respiratory drug market Research and Analysis, By Drug Class
Global Respiratory drug market Research and Analysis, By Route of Administration
Global Respiratory drug market Research and Analysis, By End User
Global Respiratory drug market Research and Analysis, By Region
The Report covers:
Comprehensive research methodology of global respiratory drug market
This report also includes detailed and extensive market overview with key analyst insights
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
Analysis of regional regulations and other government policies impacting the global respiratory drug market
Insights about market determinants which are stimulating the global respiratory drug market
Detailed and extensive market segments with regional distribution of forecasted revenues
Extensive profiles and recent developments of market players
1.1. Research Methods And Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview And Insights
2.1. Market Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.3. Pipeline Analysis
2.4. Top Respiratory Drugs Analysis
2.5. Respiratory Diseases
2.5.2. Copd (Chronic Obstructive Pulmonary Disease)
2.5.3. Cystic Fibrosis
2.5.4. Chronic Bronchitis
2.5.6. Allergic Rhinitis
2.6.1. United State
3. Market Determinant
3.1.1. High Prevalence Of Chronic Respiratory Diseases Such As Asthma And Copd
3.1.2. Growing Cases Of Respiratory Diseases In New Born And Children
3.1.3. Changing Lifestyle And Rise In Obesity
3.1.4. Innovations And Development Of New Products
3.2.1. Reimbursements And Strict Government Regulations
3.2.2. Limited Awareness And Availability
3.3.1. Robust Pipeline Products
3.3.2. Emerging Markets
4. Market Segmentation
4.1. Respiratory Drugs Market By Drug
4.1.2. Symbicort Turbuhaler
4.1.8. Relvar/Breo Ellipta
4.2. Respiratory Drugs Market By Drug Class
4.2.3. Beta2 Agonists
4.2.4. Antiasthmatic Combinations
4.2.6. Leukotriene Inhibitors
4.2.7. Mast Cell Stabilizers
4.2.8. Phosphodiesterase 4 (Pde4) Inhibitors
4.2.12. Other Respiratory Drugs
4.3. Respiratory Drugs Market By Route Of Administration
4.3.1. Oral Respiratory Drugs
4.3.2. Injectable Respiratory Drugs
4.3.3. Inhalable Respiratory Drugs
4.4. Respiratory Drugs Market By End Users
4.4.2. Home Care
4.4.3. Other End Users
5. Competitive Landscape
5.1. Market Share Analysis
5.2. Key Company Analysis
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.3. Rest Of North America
6.2.1. United Kingdom
6.2.6. Rest Of Europe
6.3. Asia Pacific
6.4. Rest Of The World
7. Company Profiles
7.1. Air Liquide
7.2. Aradigm Corporation
7.3. Astrazeneca Plc
7.4. Baxter International Inc.
7.5. Beximco Pharmaceuticals Ltd.
7.6. Boehringer Ingelheim Gmbh
7.7. Compumedics Ltd.
7.8. Covidien Plc
7.9. Drager Medical Gmbh
7.10. F. Hoffmann-La Roche Ltd
7.11. Fisher And Paykel Healthcare Corp. Ltd
7.12. Ge Healthcare Limited
7.13. Genentech, Inc.
7.14. Glaxosmithkline Plc
7.15. Grifols, S.A.
7.16. Hamilton Medical Ag
7.17. Invacare Corporation
7.18. Koninklijke Philips N.V.
7.19. Merck And Co.
7.20. Methapharm, Inc.
7.21. Mylan N.V.
7.22. Nabriva Therapeutics Plc
7.23. Nephron Pharmaceuticals Corporation
7.24. Novabiotics Ltd.
7.25. Novalung Gmbh
7.26. Novartis International Ag
7.27. Omron Corporation
7.28. Opko Health, Inc.
7.29. Orexo Ab
7.30. Otsuka Pharmaceuticals Inc.
7.31. Palobiofarma S.L.
7.32. Pfizer Inc.
7.33. Savara, Inc.
7.34. Sumitomo Dainippon Pharma Co., Ltd.
7.35. Sunovion Pharmaceuticals Inc.
7.36. Takeda Pharmaceutical Company Limited
7.37. Teva Pharmaceuticals Inc.
7.38. United Therapeutics Corporation
7.39. Valeant Pharmaceuticals International, Inc.
7.40. Verona Pharma Plc
7.41. Vertex Pharmaceuticals Inc.
- Air Liquide
- Aradigm Corporation
- Astrazeneca Plc
- Baxter International Inc.
- Beximco Pharmaceuticals Ltd.
- Boehringer Ingelheim Gmbh
- Compumedics Ltd.
- Covidien Plc
- Drager Medical Gmbh
- F. Hoffmann-La Roche Ltd
- Fisher And Paykel Healthcare Corp. Ltd
- Ge Healthcare Limited
- Genentech, Inc.
- Glaxosmithkline Plc
- Grifols, S.A.
- Hamilton Medical Ag
- Invacare Corporation
- Koninklijke Philips N.V.
- Merck And Co.
- Methapharm, Inc.
- Mylan N.V.
- Nabriva Therapeutics Plc
- Nephron Pharmaceuticals Corporation
- Novabiotics Ltd.
- Novalung Gmbh
- Novartis International Ag
- Omron Corporation
- Opko Health, Inc.
- Orexo Ab
- Otsuka Pharmaceuticals Inc.
- Palobiofarma S.L.
- Pfizer Inc.
- Savara, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Sunovion Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Inc.
- United Therapeutics Corporation
- Valeant Pharmaceuticals International, Inc.
- Verona Pharma Plc
- Vertex Pharmaceuticals Inc.